TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04841551
Drug: Kybella Flanks
Normalized name: Kybella
DrugBank: Deoxycholic acid (DB03619)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 subjects will be treated with Kybella in the flanks
Study: NCT05576818
Drug: Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
Normalized name: Lactobacillus acidophilus
DrugBank: Lactobacillus acidophilus (DB15823)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two sachets daily of synbiotic preparation containing Lactobacillus acidophilus 10 billion colony forming unit (CFU) and prebiotic fibers
Study: NCT06447402
Drug: Amphotericin B deoxycholate
Normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mL of the above reconstituted amphotericin B solution will be obtained in a sterile syringe and transferred into the drug chamber of a nebulizer. Three mL of distilled water will be added to 2 mL of the reconstituted amphotericin B (5 mL liquid in the chamber ensures complete and easy nebulization of all the contents)
Study: NCT05171439
Drug: Surufatinib
Normalized name: Surufatinib
DrugBank: Surufatinib (DB15106)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surufatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
Study: NCT04065152
Drug: Talimogene laherparepvec
Normalized name: Talimogene laherparepvec
DrugBank: Talimogene laherparepvec (DB13896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Talimogene laherparepvec
Study: NCT06461156
Drug: HS-10504
Normalized name: HS-CoM
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HS-10504 will be administered orally once daily in a continuous regimen. Participants will continue treatment until experiencing objective disease progression or meeting other protocol-specified criteria for discontinuation of study treatment.
Study: NCT04660370
Drug: CKD-348
Normalized name: CKD-504
DrugBank: CKD-504 (DB18235)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QD, PO
Study: NCT05150717
Drug: [14C]-Jaktinib
DrugBank: Jaktinib (DB17545)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will receive single dose of orally \[14C\]-Jaktinib on Day 1.
Study: NCT05296564
Drug: Aldesleukin
Normalized name: Aldesleukin
DrugBank: Aldesleukin (DB00041)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous infusion of aldesleukin 18x10E6 IU/24h will be given 24 hours post HBI 0201-ESO TCRT infusion, for four days or until a dose limiting toxicity will occur that mimics cytokine release syndrome (CRS) including blood pressure drop, oliguria or confusion- all of them or any one alone.
Study: NCT06154486
Drug: semaglutide use
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: patient using semaglutide for at least 7 days
Study: NCT05003596
Drug: Methylprednisolone Tablet
Normalized name: Methylprednisolone Tablets
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take a quantity 21 4mg tablets over a 6 week taper.
Study: NCT05037617
Drug: Continuation or discontinuation of oxytocin during the active first stage of labor (≥6 cm dilation).
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: At the intervention site (Foothills Medical Centre), for participants who consent to being part of the trial, once a patient is found to be \>= 6 cm dilation, the study medication will be initiated. Pharmacy will make up identical vials of oxytocin or saline, which will be numbered according to the random allocation sequence created by the study statistician.~The intervention will be continued until delivery unless contractions decrease to less than 2 in 10 minutes or if no further cervical dilation is noted 4 hours after discontinuation.
Study: NCT06141265
Drug: Niraparib
Normalized name: Niraparib
DrugBank: Niraparib (DB11793)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The starting dose is 300mg or 200mg QD based on the subject's baseline body weight or baseline platelet count
Study: NCT04534322
Drug: Melphalan Flufenamide
Normalized name: melphalan flufenamide
DrugBank: Melphalan flufenamide (DB16627)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Melphalan flufenamide (melflufen) is an investigational peptide-drug conjugate (PDC) that targets aminopeptidases and rapidly releases alkylating agents into tumor cells.
Study: NCT04835038
Drug: Sodium Bicarbonate Ringer's Injection
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative fluid therapy performed with BRS (Sodium Bicarbonate Ringer's Injection)
Study: NCT04835038
Drug: Sodium Lactated Ringer's Injection
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative fluid therapy performed with LRS (Sodium Lactated Ringer's Injection)
Study: NCT04534322
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone, a synthetic adrenocortical steroid, is a white to practically white, odorless, crystalline powder. It is stable in air. It is practically insoluble in water.
Study: NCT06209359
Drug: Ammonium Chloride
Normalized name: Ammonium Chloride
DrugBank: Ammonium chloride (DB06767)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be randomized to receive either ammonium chloride or placebo. Participants will receive randomized drug in combination with IV bumetanide, bendroflumethiazide, and amiloride. Following a washout period, participants will be crossed over to the alternate drug.
Study: NCT05933720
Drug: Polypeptides
Normalized name: gelatin polypeptides
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients will undergo treatment with a drug based on vascular polypeptides Slavinorm®, a derivative from cattle vessels, registered in Russia for the treatment of patients with peripheral atherosclerotic occlusive disease.
Study: NCT05823701
Drug: Chidamide
Normalized name: Chidamide
DrugBank: Tucidinostat (DB06334)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: 20 mg (4 capsules), d1, d4, d8, d11 orally per cycle
Study: NCT05823701
Drug: Azacitidine
Normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 100mg d1- d5 subcutaneous injection per cycle
Study: NCT05823701
Drug: Liposomal mitoxantrone
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg/m2 d5 intravenous infusion per cycle
Study: NCT05957848
Drug: Guanfacine Extended Release Oral Tablet
Normalized name: guanfacine Extended Release Oral Tablet
DrugBank: Guanfacine (DB01018)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Target dose 4 mg daily
Study: NCT06153238
Drug: Keytruda - EU
Normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg Q6W, i.v. infusion, over 24 weeks period
Study: NCT06153238
Drug: Keytruda - US
Normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 400 mg Q6W, i.v. infusion, over 24 weeks period
Study: NCT05411367
Drug: SI-614
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 drop in each eye
Study: NCT06444802
Drug: Linezolid
Normalized name: Linezolid
DrugBank: Linezolid (DB00601)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Linezolid dosing will be adapted according to a model informed precision dosing (TDMx)
Study: NCT04808622
Drug: Trans-Sodium Crocetinate
Normalized name: Codium tomentosum extract
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TSC given as a one-time IV bolus injection
Study: NCT03926819
Drug: HBI-002
Normalized name: HBIG
DrugBank: Hepatitis B immune globulin (DB05276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral liquid carbon monoxide drug product.
Study: NCT06026878
Drug: gemcitabine,nimotuzumab, toripalimab
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: same as before
Study: NCT06026878
Drug: gemcitabine, cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: same as before
Study: NCT05765851
Drug: T-DXd
Normalized name: T-5224
DrugBank: T-5224 (DB05998)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One IV infusion Q3W on Day 1 of each 21-day cycle
Study: NCT05149365
Drug: Sitagliptin + Standard Prophylaxis
DrugBank: Sitagliptin (DB01261)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sitagliptin 600 mg ever 12 hours orally will be given starting from the day before transplantation through day +14 after transplantation and Standard prophylaxis regimen
Study: NCT06389318
Drug: buccal midazolam +oral placebo syrup
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
Study: NCT06389318
Drug: oral chloral hydrate,intranasal dexmedetomidine and buccal normal saline
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Children received oral chloral hydrate (Chloral Hydrate mixture, concentration at 0.5gm/5ml, 250 ml bottle, prepared at abo Elreesh pharmacy, Elmoneerah , Egypt) at 50 mg /kg, intranasal dexmedetomidine at 2 μg/kg and buccal normal saline. Dexmedetomidine used was preservative-free dexmedetomidine (Precedex, 2ml ampoule,100 ug /ml, Hospira, Inc, Rocky Mount, USA) in a concentration of 100 μg/mL. Undiluted drug was withdrawn into a 1 mL tuberculin syringe.
Study: NCT06582628
Drug: Enzalutamide capsule
Normalized name: Enzalutamide Capsules
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide capsules 160 mg orally daily
Study: NCT06582628
Drug: Enzalutamide capsule and Talazoparib capsule
Normalized name: enzalutamide Oral Capsule
DrugBank: Enzalutamide (DB08899)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Enzalutamide capsules 160 mg plus talazoparib capsules 0.5 mg, both orally daily
Study: NCT00002290
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002290
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04793139
Drug: Camrelizumab
Normalized name: Camrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camrelizumab-treated advanced NSCLC Patients with advanced non-small cell lung cancer treated with camrelizumab. Dosage form, dosage, frequency and duration of camrelizumab is determined according to the investigator's actual clinical practice.
Study: NCT05889390
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: weekly paclitaxel for 12 weeks
Study: NCT05889390
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: added to weekly paclitaxel if patient has triple-negative breast cancer
Study: NCT05995782
Drug: FB418
Normalized name: Fostamatinib
DrugBank: Fostamatinib (DB12010)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Oral dose
Study: NCT06188559
Drug: BB-1701
Normalized name: BB-1701
DrugBank: BB-1701 (DB17443)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BB-1701 will be administered as an intravenous infusion, every 3 weeks (21-day cycle).
Study: NCT05805891
Drug: bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bortezomib 2mg/week subcutaneous injection
Study: NCT04467515
Drug: CAM-H2
Normalized name: phendimetrazine tartrate Oral Tablet [Cam-Metrazine]
DrugBank: Phendimetrazine (DB01579)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All patients will receive at least 1 cycle of CAM-H2. Patients with CB may receive 4 cycles of CAM-H2, each cycle given as 2 IV administrations, 4 weeks apart.
Study: NCT05157776
Drug: PD-1 and chemotherapy
Normalized name: Recombinant pd-1 mab cs1003
DrugBank: Nofazinlimab (DB18852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab+(Squamous)ABX+DDP/CBP, or (non-Squamous)PEM+DDP/CBP
Study: NCT00000712
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000712
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05499481
Drug: Antibiotic
Normalized name: Antibiotics
DrugBank: Gramicidin D (DB00027)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators will perform two concomitant RCTs, depending on the presence of infected osteosynthesis material at enrolment:~- SALATIO 1. Infected implant not removed (or new material inserted): Randomization 6 vs. 12 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.~- SALATIO 2. Infected implant without residual material (definitive removal or within the interval of a two-stage exchange): Randomization 3 vs. 6 weeks (+/- 5 days) of total antibiotic therapy counted since the first debridement for infection. Early switch to oral targeted therapy.
Study: NCT04531215
Drug: ultrasound guided Retrolaminar Block
Normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ultrasound guided Retrolaminar Block (RLB) with 20 ml (0.5% Bupivacaine) plus 5 mic/ml Adrenaline (1:200,000) at the level of T4 of the surgical side
Study: NCT05953350
Drug: 600mg bid dose of hydroxychloroquine combined with three predefined dose groups of palbociclib
Normalized name: COMBINATIONS OF ANTIBACTERIALS
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hydroxychloroquine group of 600mg bid combined with three predefined dose groups of palbociclib: 100mg QD, 150mg QD, and 200mg QD, separately.
Study: NCT05953350
Drug: RP2D dose of 600mg bid of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: After the exploration of 600mg bid dose of hydroxychloroquine combined with palbociclib, and the maximal tolerated dose (MTD) was determined, then RP2D dose of 600mg bid dose of hydroxychloroquine combined with palbociclib was selected for phase II clinical trial.
Study: NCT04895306
Drug: Testosterone Cypionate
Normalized name: Testosterone Cypionate
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly intramuscular administration of testosterone at a dose of 3 mg
Study: NCT06141876
Drug: APEX-002-A02
Normalized name: Apexicon
DrugBank: Diflorasone (DB00223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active
Study: NCT04651361
Drug: Dinalbuphine sebacate
Normalized name: Dinalbuphine sebacate
DrugBank: Dinalbuphine sebacate (DB15341)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naldebain dissolved in benzyl benzoate and sesame oil (a total volume of 2ml) will be prepared in a 5-ml syringe 30 min before administration. Intramuscular injection into the gluteal muscles will be performed by an anesthesiologist under sonography-guidance.
Study: NCT06370949
Drug: Bupivacain
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ultrasonography (USG) guided bilateralTAP block:20 ml %0,25 concentration bupivacain
Study: NCT06370949
Drug: bupivacain+dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ultrasonography (USG) guided bilateral TAP block: 20 ml %0,25 concentration bupivacain+ 0.5 mcg/kg dexmedetomidine
Study: NCT05319028
Drug: Mivavotinib
Normalized name: Mivavotinib
DrugBank: Mivavotinib (DB16849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral tablet
Study: NCT04861376
Drug: Pueraria thomsoni
Normalized name: PUERARIA MIRIFICA ROOT
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The dose of Pueraria thomsoni granules is one sachet per day, 1.5g per sachet, which equivalent to 15g of the original drug.
Study: NCT06362590
Drug: ladiratuzumab vedotin
Normalized name: Ladiratuzumab vedotin
DrugBank: Ladiratuzumab vedotin (DB15409)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT06076759
Drug: Intrathecal morphine or dexmedetomidine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecal injection
Study: NCT04635683
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04635683
Drug: Umbralisib
Normalized name: Umbralisib
DrugBank: Umbralisib (DB14989)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02649153
Drug: smoked plum
DrugBank: Plum (DB10560)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus
Study: NCT02649153
Drug: gum chewing
Normalized name: Nicotine (as nicotine polacrilex) 4 mg oral gum chewing gum
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
Study: NCT05756153
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab administered intravenously Q2W.
Study: NCT05433922
Drug: Avatrombopag
Normalized name: AVATROMBOPAG
DrugBank: Avatrombopag (DB11995)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: cyclosporine in combination with Avatrombopag to treat
Study: NCT05520827
Drug: BI 1584862
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1584862
Study: NCT05572268
Drug: to evaluate the safety and efficacy of Ansa for the treatment of UTi and control of Ecoli infection
Normalized name: Extract of the Sterile Caules of Equisetum Arvense
DrugBank: Fica (DB03384)
Approvals — FDA: no, EMA: no, PMDA: no
Description: to evaluate the safety and efficacy of Cranmax for the treatment of UTi and control of Ecoli infection
Study: NCT05197023
Drug: SHR-1819 injection or placebo
Normalized name: INV-CSP #2002 METFORMIN OR PLACEBO
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drug: SHR-1819 injection or placebo Low-dose group, once per week Drug: SHR-1819 injection or placebo High-dose group, once per week
Study: NCT05165290
Drug: Latanoprost ophthalmic solution, 0.005%
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Commercially available, FDA-approved generic latanoprost ophthalmic solution, 0.005% (LAT) without modification will be used as the active control
Study: NCT05165290
Drug: TC-002 latanoprost ophthalmic solution, 0.005%
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: TC-002 is formulated using the commercially available latanoprost drug substance; delivered drop to the eye is preservative-free.
Study: NCT04996485
Drug: Secukinumab Injection
Normalized name: Secukinumab Injection
DrugBank: Secukinumab (DB09029)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pathogenetic therapy with biologic drugs
Study: NCT04996485
Drug: Ustekinumab Injection
Normalized name: ustekinumab Injection
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pathogenetic therapy with biologic drugs
Study: NCT04996485
Drug: Dupilumab Injection
Normalized name: dupilumab Injectable Product
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pathogenetic therapy with biologic drugs
Study: NCT05638893
Drug: Metformin Hcl 500Mg Tab
Normalized name: METFORMIN HCL 500MG TAB
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (500mg/12hr) + celecoxib (200mg/day) for three months.
Study: NCT00034086
Drug: Lopinavir/Ritonavir
Normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00034086
Drug: Lamivudine/Zidovudine
Normalized name: LAMIVUDINE/ZIDOVUDINE
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00034086
Drug: Tenofovir disoproxil fumarate
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00034086
Drug: Lamivudine
Normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00034086
Drug: Stavudine
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00034086
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00034086
Drug: Didanosine
Normalized name: Didanosine
DrugBank: Didanosine (DB00900)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04034004
Drug: Naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A 0.15 mg/kg bolus dose of naloxone (Naloxone hydrochloride, Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, California) in 25ml normal saline will be administered over 10 minutes. The investigators also will administer a supplementary IV infusion dose of 0.1mg/kg/hour naloxone immediately after bolus infusion will cease till the end of the experiment.
Study: NCT06241105
Drug: Lenvatinib+Toripalimab.
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjustment of Medication Dosage: Throughout the course of treatment, adjustments should be made exclusively to the dosage of the drug Lenvatinib.The starting dosage for lenvatinib is 8 mg, administered orally once a day for a period of four weeks. If no adverse reactions are observed, the dosage can be escalated to 12 mg for individuals weighing over 60 kg. However, if the patient experiences intolerable side effects, the dosage should be decreased back to 8 mg.For individuals weighing less than 60 kg, the maximum dosage is 8 mg per day. Should adverse reactions become intolerable, the dosage may be decreased to 4 mg per day.Withdrawal from the study if still intolerable.
Study: NCT04871607
Drug: Carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04871607
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04871607
Drug: Etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT03206931
Drug: Selitrectinib (BAY2731954)
Normalized name: entrectinib
DrugBank: Selitrectinib (DB14896)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Selitrectinib is administered as capsules or liquid formulation.
Study: NCT05122091
Drug: Fruquintinib + SOX
DrugBank: Fruquintinib (DB11679)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fruquintinib：5mg qd for 2 weeks on and 1 week off, q3w； SOX: Tegafur gimeracil oteracil potassium capsule: 40-60mg bid（dosage according to body surface area），d1-14，q3w； Oxaliplatin：130mg/m2，intravenous (IV) ，d1，q3w.